These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 10918951)
41. Evaluation of the urinary threshold concentration of formoterol in sports drug testing. Ventura R; Damasceno LM; Ramírez R; Farré M; Bergés R; Segura J Drug Test Anal; 2013 Apr; 5(4):266-9. PubMed ID: 23355217 [TBL] [Abstract][Full Text] [Related]
42. Quantitative determination of the beta-adrenoceptor stimulant formoterol in urine by gas chromatography mass spectrometry. Kamimura H; Sasaki H; Higuchi S; Shiobara Y J Chromatogr; 1982 May; 229(2):337-45. PubMed ID: 6124550 [TBL] [Abstract][Full Text] [Related]
43. Bioequivalence assessment of inhalation products: Interchangeability, study design and statistical methods. Arieta AG Pulm Pharmacol Ther; 2010 Jun; 23(3):156-8. PubMed ID: 20064625 [No Abstract] [Full Text] [Related]
49. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers. Weisfeld L; Shu Y; Shah TP Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol. Grekas N; Athanassiou K; Papataxiarchou K; Rizea Savu S; Silvestro L J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292 [TBL] [Abstract][Full Text] [Related]
53. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841 [TBL] [Abstract][Full Text] [Related]
54. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers. Petzold U; Kremer HJ; Nguyen DT; Munzel U; Dietrich H; Maus J J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):309-19. PubMed ID: 18598160 [TBL] [Abstract][Full Text] [Related]
55. The use of inhaled formoterol in the treatment of asthma. Berger WE Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777 [TBL] [Abstract][Full Text] [Related]
56. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Molimard M; Till D; Stenglein S; Singh D; Krummen M Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055 [TBL] [Abstract][Full Text] [Related]
57. Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic, safety and urinary pharmacokinetic data. Marzo A; Monti NC; Tettamanti RA; Crivelli F; Dal Bo L; Mazzucchelli P; Meoli A; Pezzuto D; Corsico A Arzneimittelforschung; 2000 Jun; 50(6):559-63. PubMed ID: 10918951 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908 [TBL] [Abstract][Full Text] [Related]